Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 7;11:788245. doi: 10.3389/fonc.2021.788245

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Patil, Nie, Aisner and Camidge

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Representative images from patients in this case series. (A) CT imaging from a 58-year-old male former smoker with a diagnosis of stage IVB NSCLC with an adenosquamous histology harboring a CD74-ROS1 fusion upon progression on entrectinib and prior to use of carboplatin, pemetrexed and pembrolizumab. (B) CT imaging of best-treatment response with significant reduction in the size of the left supraclavicular lymph node. (C) PET/CT imaging from a 40-year-old male never smoker with stage IVB NSCLC with an adenosquamous histology harboring an EML4-ALK fusion prior to treatment with single agent pemetrexed. (D) PET/CT imaging demonstrating significant improvement within known right paratracheal nodes.